NASDAQ:BPTH - Bio-Path Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bio-Path Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.32 -0.18 (-3.27 %) (As of 02/28/2020 10:45 AM ET) Add Compare Today's Range$5.30Now: $5.32▼$5.4050-Day Range$5.50MA: $6.69▼$7.6452-Week Range$1.98Now: $5.32▼$73.52Volume17,285 shsAverage Volume75,184 shsMarket Capitalization$15.32 millionP/E RatioN/ADividend YieldN/ABeta3.03 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BPTH Previous Symbol CUSIPN/A CIK1133818 Webhttp://www.biopathholdings.com/ Phone832-742-1357Debt Debt-to-Equity Ratio0.02 Current Ratio13.85 Quick Ratio13.85Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$40,000.00 Price / Sales383.04 Cash FlowN/A Price / Cash FlowN/A Book Value$1.79 per share Price / Book2.97Profitability EPS (Most Recent Fiscal Year)($14.38) Net Income$-8,580,000.00 Net MarginsN/A Return on Equity-58.73% Return on Assets-53.62%Miscellaneous Employees8 Outstanding Shares2,880,000Market Cap$15.32 million Next Earnings Date3/18/2020 (Estimated) OptionableNot Optionable Receive BPTH News and Ratings via Email Sign-up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:BPTH Rates by TradingView Bio-Path (NASDAQ:BPTH) Frequently Asked Questions What is Bio-Path's stock symbol? Bio-Path trades on the NASDAQ under the ticker symbol "BPTH." When did Bio-Path's stock split? How did Bio-Path's stock split work? Bio-Path's stock reverse split before market open on Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 17th 2019. An investor that had 100 shares of Bio-Path stock prior to the reverse split would have 5 shares after the split. How were Bio-Path's earnings last quarter? Bio-Path Holdings Inc (NASDAQ:BPTH) issued its quarterly earnings results on Wednesday, August, 15th. The company reported ($3.00) earnings per share for the quarter, topping the consensus estimate of ($4.00) by $1.00. View Bio-Path's Earnings History. When is Bio-Path's next earnings date? Bio-Path is scheduled to release their next quarterly earnings announcement on Wednesday, March 18th 2020. View Earnings Estimates for Bio-Path. What price target have analysts set for BPTH? 1 brokerages have issued 1 year price targets for Bio-Path's stock. Their forecasts range from $25.00 to $25.00. On average, they expect Bio-Path's stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 369.9% from the stock's current price. View Analyst Price Targets for Bio-Path. What is the consensus analysts' recommendation for Bio-Path? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bio-Path. What are Wall Street analysts saying about Bio-Path stock? Here are some recent quotes from research analysts about Bio-Path stock: 1. According to Zacks Investment Research, "BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized. " (2/3/2020) 2. HC Wainwright analysts commented, "We believe quarterly operating expenses could approximate $2M in 2H19. The company had $17.1M in cash at the end of June 2019, which should support operations into 2H20. In the wake of this update, we reiterate our Buy rating and $28 price target. Combo trial of prexigebersen + decitabine could report safety data in 2H19. Prexigebersen is an antisense DNA molecule that blocks expression of growth factor receptor-bound protein 2 (Grb-2). Prexigebersen has shown favorable safety and positive Phase 2 interim data in combination with low-dose cytarabine (LDAC) in elderly patients with acute myeloid leukemia (AML), demonstrating 65% objective response with a 29% complete response (CR) rate." (8/16/2019) Has Bio-Path been receiving favorable news coverage? Media coverage about BPTH stock has been trending extremely negative this week, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Bio-Path earned a news sentiment score of -4.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Bio-Path. Are investors shorting Bio-Path? Bio-Path saw a decline in short interest in February. As of February 14th, there was short interest totalling 44,300 shares, a decline of 66.5% from the January 30th total of 132,200 shares. Based on an average daily trading volume, of 156,500 shares, the short-interest ratio is currently 0.3 days. Approximately 1.7% of the shares of the stock are short sold. View Bio-Path's Current Options Chain. Who are some of Bio-Path's key competitors? Some companies that are related to Bio-Path include CNS Pharmaceuticals (CNSP), Trevena (TRVN), DiaMedica Therapeutics (DMAC), Alpine Immune Sciences (ALPN), Catabasis Pharmaceuticals (CATB), Soligenix (SNGX), Q BioMed (QBIO), CTI BioPharma (CTIC), SCYNEXIS (SCYX), American Brivision (Holding) (ABVC), NewLink Genetics (NLNK), Processa Pharmaceuticals (PCSA), PLx Pharma (PLXP), resTORbio (TORC) and Vascular Biogenics (VBLT). What other stocks do shareholders of Bio-Path own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), TrovaGene (TROV), Canopy Growth (CGC), Agile Therapeutics (AGRX), Amarin (AMRN), OpGen (OPGN), Anavex Life Sciences (AVXL) and Trevena (TRVN). Who are Bio-Path's key executives? Bio-Path's management team includes the folowing people: Mr. Peter H. Nielsen, Co-Founder, Chairman, CEO, Pres, CFO & Treasurer (Age 70)Mr. Douglas P. Morris, Co-Founder, Director of Investor Relations, Sec. & Director (Age 63)Mr. Anthony Price MBA, Director of Fin. and AccountingDr. Alan MacKenzie Ph.D., ConsultantDr. Thomas A. Walker Ph.D., Consultant Who are Bio-Path's major shareholders? Bio-Path's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.35%). View Institutional Ownership Trends for Bio-Path. Which institutional investors are buying Bio-Path stock? BPTH stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can. View Insider Buying and Selling for Bio-Path. How do I buy shares of Bio-Path? Shares of BPTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Bio-Path's stock price today? One share of BPTH stock can currently be purchased for approximately $5.32. How big of a company is Bio-Path? Bio-Path has a market capitalization of $15.32 million and generates $40,000.00 in revenue each year. The company earns $-8,580,000.00 in net income (profit) each year or ($14.38) on an earnings per share basis. Bio-Path employs 8 workers across the globe.View Additional Information About Bio-Path. What is Bio-Path's official website? The official website for Bio-Path is http://www.biopathholdings.com/. How can I contact Bio-Path? Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The company can be reached via phone at 832-742-1357 or via email at [email protected] MarketBeat Community Rating for Bio-Path (NASDAQ BPTH)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 253 (Vote Outperform)Underperform Votes: 221 (Vote Underperform)Total Votes: 474MarketBeat's community ratings are surveys of what our community members think about Bio-Path and other stocks. Vote "Outperform" if you believe BPTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPTH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/28/2020 by MarketBeat.com StaffFeatured Article: What is the Coverage Ratio?
